Pharmaceutical company Lundbeck in collaboration with Magnitude Biosciences on innovative new platform to test interventions for neurodegenerative disease

We are delighted to announce our collaboration with Lundbeck, a global pharmaceutical company specialized in brain diseases. We are working to provide a new model to develop drugs for devastating neurodegenerative movement disorders using the nematode worm C. elegans. The model, made by expressing human genes found in patients will enable Lundbeck to find new interventions which, like the disease, act during development.

Neurodegeneration produces behavioural changes with profound effects on quality of life that cannot be replicated in in vitro models. Testing compounds that could slow the degeneration of neurons in a mammalian model are limited by time, expense and regulation. Magnitude Biosciences use the nematode worm C. elegans to quickly generate models of neurodegenerative disease through overexpression of human proteins implicated in neurodegenerative diseases, which leads to loss of function phenotypes that can be scored and used to test interventions. Our automated data acquisition, robust methodology and processes help us conduct experiments quickly with high reproducibility. Lundbeck approached Magnitude Biosciences as a world- leading C. elegans CRO. This collaboration is an example that we can adapt to the needs of a wide range of disease-specific challenges in drug discovery.

"We are excited to be working with Magnitude Biosciences. Their unique approach to generating in vivo data for studying disease models will hopefully help us get fast and reliable answers to our research questions."

- Kjartan Herrik, Principal Scientist at Lundbeck

Please look out for the results of this collaboration, which will be shared in the public domain.

To find out how Magnitude Biosciences can support your research contact us via 

Press Contact:

Jessica Evans

Related News

Magnitude Biosciences: Revolutionising Research
Contract research organisation Magnitude Biosciences is projecting significant growth as it looks to...Read More
Life Sciences consortium celebrate collective multi-million Biomedical Catalyst 2023 Innovate UK grant
Press Release: 24th July 2023 Photo:  From left to right: Prof Carrie Ambler, (LightOx) Dr Sam Whit...Read More
Magnitude Biosciences awarded grant to accelerate the identification of compounds that could slow ageing or treat age-related diseases
Photo: The Magnitude Biosciences Team May 2023, Sedgefield, United Kingdom Magnitude Biosciences Lim...Read More
AB Biotek works with Magnitude Biosciences to accelerate probiotic development
Magnitude Biosciences partnered with AB Biotek Human Nutrition & Health (ABB HNH), the global le...Read More
Pharmaceutical company Lundbeck in collaboration with Magnitude Biosciences on innovative new platform to test interventions for neurodegenerative disease
Lundbeck collaborates with Magnitude on innovate platform to test neurodegenerative disease interven...Read More
Magnitude Biosciences secures new investment to accelerate scaling of its specialist anti-ageing research services
Magnitude Biosciences Limited, a specialist provider of C. elegans research services to the longevit...Read More
Magnitude Biosciences Appoints New CEO Fozia Saleem to Drive Growth
North East UK Biotech Magnitude Biosciences announces new CEO, Fozia Saleem, to accelerate the growt...Read More
SMER28 Extends Healthspan – Revealing a New Target for Ageing Therapeutics
Biotech entrepreneur Ethan Perlstein works with Magnitude Biosciences to reveal a new target for age...Read More
Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing
The British Society for the Research on Ageing (BSRA) announces its new Chair, biology of ageing res...Read More
Frontiers in Aging: Applying C. elegans to industrial drug discovery
Just published in Frontiers in Aging: Applying C. elegans to industrial drug discovery...Read More
Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms
The joint project for Magnitude Biosciences, Perfectus Biomed Group and the University of Kent aims ...Read More
Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand
Durham, UK - July 29, 2021 Magnitude Biosciences, the world’s leading commercial lab services prov...Read More
Magnitude Biosciences recognised in Developed in Durham as local success story
Magnitude Biosciences has been recognised by Developed in Durham....Read More
The worm angle on the taurine story: a route to the clinic by understanding mechanism
Dr Manish Chamoli in the lab of Gordon Lithgow at the Buck Institute (Right) David Weinkove, 15 June...Read More
Magnitude Biosciences secures its second round of funding to support its pre-clinical research services
Magnitude Biosciences secures its second round of funding to support its pre-clinical research servi...Read More
Magnitude Biosciences announces new hires to support continued growth
Durham, UK - March 2021 Magnitude Biosciences, a spin-out from Durham University and the leading con...Read More
Magnitude Biosciences secures UK government Future Fund to expand its workforce.
Durham, UK - August 2020 Research into new medicines is needed more than ever, but research labs acr...Read More
Magnitude Biosciences' new COVID-19 compatible laboratory is fully operational and we are ready to support your research
Magnitude Biosciences moves its unique COVID-19 compatibletechnology to a new lab at NETPark in Sedg...Read More

Get regular updates in your inbox

Sign up to our newsletter today, to get access to the latest company and industry news